Cancer Resources
Featured Centers
- Eating Out? Cut Calories, Heartburn
- 5 Good Ways to Save Money on Medicine
- 8 Ways to Treat Your Allergies
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
ARZERRA® (ofatumumab) is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
The effectiveness of ARZERRA is based on the demonstration of durable objective responses [see Clinical Studies]. No data demonstrate an improvement in disease-related symptoms or increased survival with ARZERRA.
Read the complete drug monograph for Arzerra »
Drug Description - Indications & Dosage - Side Effects & Drug Interactions - Warnings & Precautions - Contraindications - Medication Guide and More
What is Consumer information?
A concise overview of the drug for the patient or caregiver from First DataBank.
HOW TO USE: This medication is given by injection into a vein by a health care professional. It is usually given once a week for the first 8 doses, then once every 4 weeks for the last 4 doses or as directed by your doctor. ...
Read the complete consumer information for Arzerra »
Warnings - Uses - How to Use - Side Effects - Precautions - Drug Interactions and More
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.